RT Journal Article
SR Electronic
T1 The impact of the COVID-19 pandemic on rabies reemergence in Latin America: the case of Arequipa, Peru
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.06.20169581
DO 10.1101/2020.08.06.20169581
A1 Brinkley Raynor
A1 Elvis W. Díaz
A1 Julianna Shinnick
A1 Edith Zegarra
A1 Ynes Monroy
A1 Claudia Mena
A1 Ricardo Castillo-Neyra
YR 2020
UL http://medrxiv.org/content/early/2020/08/11/2020.08.06.20169581.abstract
AB Over the past decades, there has been tremendous progress towards eliminating canine rabies in Latin America. Major components of rabies prevention programs in Latin America leading to these successes have been constant and intense surveillance for rabid dogs and uninterrupted yearly mass dog vaccination campaigns. However, vital measures to control COVID-19 in Latin America have had the negative trade-off of jeopardizing these rabies elimination and prevention activities. In this paper, we aimed to assess the effect of interrupting canine rabies surveillance and mass dog vaccination campaigns on rabies trends. We built a deterministic compartment model of dog rabies dynamics parameterized for conditions found in Arequipa, Peru, where there is an ongoing dog rabies epidemic. Our model suggests that a decrease in canine vaccination coverage as well as decreased surveillance leading to an increased length of survival of infected dogs could lead to a sharp rise in canine rabies and, subsequently, human rabies risk. We examined our results over the best estimate of the basic reproductive number in Arequipa (R0 = 1.44) and a range of plausible values for R0 (1.36 - 2). The rising trend was consistent. It is very possible that COVID-19 will continue to challenge our public health departments in the short- and medium-term. Innovative strategies to conduct dog vaccination and rabies surveillance during these trying times should be considered to safeguard the achievements made in Latin America towards the elimination of dog-mediated human rabies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Castillo-Neyra was supported by NIH-NIAID grant 1K01AI139284. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Parameters were extracted from literature or obtained from analyses of secondary data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesParameters were extracted from literature or obtained from analyses of secondary data. Secondary data are available at the Peruvian Ministry of Health upon request.